Breaking News

Cytori Appoints CFO

August 19, 2014

Girão replaces Saad

Tiago Girão has been appointed vice president of finance and chief financial officer at Cytori Therapeutics, effective September 2, 2014. Mr. Girão replaces Mark Saad, who has left the company to pursue other interests.
Mr. Girão joins the company from NuVasive, Inc., where he recently served as International Controller, responsible for leading the finance team and overseeing all aspects of international finance and accounting operations. He was also involved in all major business and asset acquisitions and was the lead corporate financial and accounting executive for NuVasive’s foreign units. Prior to joining NuVasive, Mr. Girão served as senior manager of assurance at KPMG, Cytori’s independent audit firm and was responsible for Cytori’s account for six years.  
“Mr. Girão is an ideal candidate to take over the role at this time in our corporate development,” said Dr. Hedrick. “He has a particularly strong background in public company finance and accounting practices as well as international operations, all important issues for us today. The added benefit to Cytori is that he has an in-depth, long standing knowledge of Cytori’s technology and history from his previous tenure at KPMG in which he functioned as the senior account manager for Cytori. This will enable him to get up to speed quickly and we are extremely excited to have him on our team.”
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision